agreement

December 19, 2017December 19, 2017

Pharmaxis, Synairgen Update Partnership to Advance Potential IPF Treatment in Clinical Trial

Pharmaxis and Synairgen have revised their Lysyl Oxidase type 2 enzyme (LOXL2) program collaboration agreement, after obtaining positive results in preclinical studies and launching a Phase 1 clinical trial. Strong evidence suggests that ... Read more

July 19, 2017July 19, 2017

Sunovion Divests US Market Rights on Asthma and Allergic Rhinitis Therapies to Focus on COPD

Asthma, COPD, News

Sunovion Pharmaceuticals has entered an agreement with Covis Pharma to divest the U.S. market rights of a series of products based on ciclesonides approved for the treatment of asthma and allergic rhinitis. Ciclesonides are in ... Read more

June 5, 2017June 5, 2017

Irish Health Service Covers Vertex’s Cystic Fibrosis Therapies Orkambi and Kalydeco

Cystic Fibrosis, News

Hundreds of cystic fibrosis patients in Ireland have obtained national health service coverage for the Vertex Pharmaceuticals therapies Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor). The agreement between the Irish Health Service Executive and Vertex ... Read more

May 4, 2016May 4, 2016

Galapagos, AbbVie Expand Collaboration on Cystic Fibrosis Treatments

Cystic Fibrosis, News

Galapagos NV and AbbVie are expanding their collaboration to continue their successful portfolio growth in cystic fibrosis (CF). The two companies are committed to increasing the potential milestones to Galapagos for Phase ... Read more